4 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Recruiting 3, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
Follow Primary Mediastinal Large B-Cell Lymphoma: new trials by email Literature Review of Primary Mediastinal Large B-Cell Lymphoma trials Research Report on Primary Mediastinal Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 120 | 2024-01-31 | 2024-09-26 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs Decitabine, GVD chemotherapy, SHR-1210 - Primary Mediastinal Large B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-05-01 | 2018-12-03 |
| Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) MDV9300 - Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | Medivation, Inc. | 2016-12-01 | 2016-11-25 | |
| Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma Ruxolitinib - Relapsed or Refractory Hodgkin Lymphoma, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | Samsung Medical Center | 20 | 2013-11-15 | 2018-11-01 |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Tazemetostat, Prednisolone - B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1) | Phase 1 / Phase 2 | Completed | Epizyme, Inc. | 400 | 2013-06-13 | 2024-03-26 |
| CT-011 MAb in DLBCL Patients Following ASCT CT-011 - Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse | Phase 2 | Completed | CureTech Ltd | 72 | 2007-10-01 | 2014-09-12 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 348 | 1993-05-08 | 2025-06-22 |
Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, Follicular (3) · Recurrence (3) · Burkitt Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoma (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphoma, B-Cell (7) · Lymphoma, Non-Hodgkin (7) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · DNA Virus Infections (2) · Epstein-Barr Virus Infections (2)
Cyclophosphamide (4) · Biopsy (3) · Doxorubicin (3) · Etoposide (3) · Prednisone (3) · Rituximab (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · deltacortene (2) · Antibodies, Monoclonal (1) · CT-P10 (1) · Decitabine (1) · Dexamethasone (1) · Dioctyl Sulfosuccinic Acid (1) · Emapalumab (1)
University of Washington (2) · Academic and Community Cancer Research United (1) · Chinese PLA General Hospital (1) · CureTech Ltd (1) · Epizyme, Inc. (1) · Genmab (1) · Marcela V. Maus, M.D.,Ph.D. (1) · Medivation, Inc. (1) · National Cancer Institute (NCI) (1) · Samsung Medical Center (1)
United States (9) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1)
Arnon Nagler, MD (1) · Grzegorz S Nowakowski (1) · Leo I Gordon, MD (1) · Mark J Roschewski, M.D. (1) · Matthew Frigault, MD (1) · Mengyang Di, MD, PhD (1) · Ryan Lynch (1) · Won Seog Kim, PhD (1)
PMID 23574119, PMID 24127452, PMID 24224624, PMID 25024303, PMID 29650362, PMID 29748435, PMID 30125215, PMID 31707975, PMID 33035457, PMID 34432874, PMID 35882475, PMID 36521030, PMID 37981564, PMID 39563886, PMID 40802906
2019 (1), P30CA015083 (1)